Electrophysiologic and antiarrhythmic effects of the new class III antiarrhythmic drug KCB-328 in experimental canine atrial flutter.
BACKGROUND
The electrophysiologic and antiarrhythmic effects of a new class III antiarrhythmic drug (KCB-328), a delayed rectifier potassium current (IKr) blocker with minimal reverse use-dependent effect on atrial repolarization, were evaluated in the canine night atrial crush-injury model of atrial flutter (AFL).


METHODS
Ten anesthetized, open-chest dogs, were studied after right atrial crush-injury. Atrial effective refractory period (ERP), conduction velocity (CV), wavelength, and dispersion of refractoriness were determined during programmed stimulation (S1S2 at S1S1 = 200, 300, 400, and 500 msec) at four sites via a mapping plaque sutured on the right atrial free wall. Right and left ventricular ERP were similarly measured at single sites. Electrophysiological parameters were determined at baseline and following sequential cumulative doses of KCB-328 (10, 30, 100, and 300 microg/kg).


RESULTS
Sustained AFL was inducible in 7/10 dogs by rapid pacing following baseline electrophysiologic measurements. KCB-328 significantly prolonged sinus cycle length, but had no effect on PR interval, and prolonged QTc only at the highest dose level. KCB-328 significantly prolonged atrial ERP and wavelength and ventricular ERP, and significantly reduced dispersion of atrial refractoriness. KCB-328 significantly prolonged AFL cycle length, and increasing doses progressively terminated sustained AFL and prevented its reinduction by pacing. No adverse hemodynamic or ventricular proarrhythmic effects were observed.


CONCLUSIONS
The electrophysiologic profile of KCB-328 in this canine model of AFL, particularly its lack of reverse use-dependent effect on atrial refractoriness, suggests that it may have significant antiarrhythmic potential in treatment of atrial arrhythmias.
Rahme
M M
MM
Cardiac Electrophysiology Program, Division of Cardiology, Department of Medicine, University of California, San Diego, CA 92103, USA.
Ungab
G A
GA
Wadhwa
M
M
Al-Kandari
F
F
Yao
B
B
Gupta
A
A
Lee
K
K
Kim
H Y
HY
Feld
G K
GK
D000818:Animals; D000889:Anti-Arrhythmia Agents / Q000008:administration & dosage / Q000145:classification / Q000627:therapeutic use*; D001282:Atrial Flutter / Q000188:drug therapy* / Q000503:physiopathology; D004195:Disease Models, Animal; D004285:Dogs; D004562:Electrocardiography / Q000187:drug effects*; D022062:Electrophysiologic Techniques, Cardiac / Q000379:methods; D007261:Infusions, Intra-Arterial; D007262:Infusions, Intravenous; D010627:Phenethylamines / Q000008:administration & dosage / Q000097:blood / Q000627:therapeutic use*; D013449:Sulfonamides / Q000008:administration & dosage / Q000097:blood / Q000627:therapeutic use*
C112304:1-(2-amino-4-methanesulfonamidophenoxy)-2-(N-(3,4-dimethoxyphenethyl)-N-methylamino)ethane; D000889:Anti-Arrhythmia Agents; D010627:Phenethylamines; D013449:Sulfonamides